Trial Profile
A Randomized, Phase 2 Study of Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 27 Aug 2019 Status changed from active, no longer recruiting to completed.
- 05 Jul 2018 Status changed from recruiting to active, no longer recruiting.
- 09 Jun 2017 Planned primary completion date changed from 1 Apr 2018 to 1 Aug 2018.